SUZHOU, China, March 20, 2023 /PRNewswire/ -- The management team of Transcenta Holding Limited (06628.HK) will attend the 2022 annual results release conference call on March 31, 2023. Transcenta is a clinical stage biopharmaceutical company with fully integrated capabilities in the discovery, research, development and manufacture of antibodies-based therapeutics.

Meeting Details:

MeetingDate:	Friday, March 31, 2023
Meeting time:	10:00 a.m. (Beijing time)
Meeting Language:	English
Attendance Management:	Dr. Xueming Qian, Chief Executive Officer
Dr. Caroline Germa, EVP, Global Medicine Development and CMO
Mr. Daniel Weng, EVP, CFO
Ms. Vivian Wang, VP, Investor Relations & Capital Markets, Board Secretary
Enrollment form:	Please scan the QR code to register (please register before March 27, 2023) https://forms.ebdan.net/ls/5hp2szk2?bt=yxy

About Transcenta Holding Limited

Transcenta is a clinical stage biopharmaceutical company that fully integrates biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Princeton, US and in Beijing, Shanghai and Guangzhou in China, and External Partnering Center in Boston and Los Angeles, US. Transcenta has also initiated the construction of the Group Headquarters and the second high-end biopharmaceutical facility with ICB as its core technology in Suzhou Industrial Park. Transcenta is developing ten therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

For more information about Transcenta, please visit

Website: www.transcenta.com

Linkedin: Transcenta

Source: Transcenta Holding Limited Related Stocks: HongKong:6628